Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics
Tuesday: the Francis Crick Institute announced its application to conduct new research on human embryos
Wednesday: Israeli NovoCure announced an IPO on NASDAQ with a target of €170M
Thursday: Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy
Friday: in a successful phase III trial, the Amgen biosimilar showed full-efficacy equivalent to Roche‘s Avastin